



Press Release
Chatou, January 18th, 2023

Mayoly appoints a new executive committee to support its ambitious development goals

Following the acquisition of Ipsen's Consumer Healthcare (Ipsen CHC), completed in July 2022, Mayoly adapts its governance and is pleased to announce the appointment of a new executive team led by its CEO, Nicolas Giraud.

With 10 members in charge of 8 departments, this new executive committee has a two-fold roadmap: complete the integration process of Ipsen CHC within Mayoly; and build a unified team to deliver on its development targets. With 2,200 employees across all continents, the new group ambitions to be one of the leading consumer healthcare companies, leveraging its strong brands (Topicrem, Smecta, Probiolog, etc.) and recognised specialities, most notably in gastroenterology and dermocosmetics.

This new executive committee reflects the mix of cultures within the group, with three executives from Ipsen CHC, six from Mayoly and one external hire. In addition, four new divisions have been created, three of which are fully dedicated to brand development (Global marketing CHC, M&A and Alliances, Strategy & Business transformation).

The executive committee is organised around 8 divisions reporting to Nicolas Giraud:

- **Global Sales**, led by Emmanuel Paint. This activity includes all subsidiaries, the Diagnostic BU and the Dermo-Cosmetic Business Unit, under the leadership of Vincent Bercovici, who also sits on the Executive Committee.
- **Global Marketing CHC**, led by Roberto Nakahara, who is joining the Group from February 6th, 2023. Roberto brings more than 20 years of consumer, OTC and CHC marketing experience in major international groups.
- **Global Scientific Affairs**, which includes medical and regulatory affairs, patient safety & Medical information and R&D led by Nawel Moumen.
- **Industrial Operations**, including the 6 plants (5 of which are in France), led by Sébastien Nicolas.
- **Finance and Administration**, under the direction of Christophe Hamon, including legal & compliance, digital & information systems and indirect purchasing.
- **Human Relations, Communications and CSR**, led by Christophe Napiot.
- **M&A and Alliances**, which includes M&A and Business Development activities, headed by Emmanuel Botzung.
- **Strategy & Business Transformation**, which includes the Project Management Office (including the integration), Product Innovation, Strategic Planning and Internal Audit, led by Alexandre Fuzier.

"The experience, industry expertise and leadership skills of the members of this new executive committee put Mayoly in the best position to deliver on its ambitious development goals. This new management brings together a team of talented individuals from Mayoly and Ipsen CHC, as well as an external hire, to work as one team in order to provide safe, effective and affordable healthcare solutions to the greatest number of people," said Nicolas Giraud, Chief Executive Officer of Mayoly. "I have utmost confidence in this team to turn Mayoly into a major player of the Consumer Healthcare industry in the coming years, building on its 2,200 employees."

Contacts

Jean-Benoit Harel / jean-benoit.harel@vae-solis.com / +33 7 60 84 52 72

Alexis de Maigret / alexis.demaigret@vae-solis.com / + 33 6 13 62 38 23

About Mayoly

Founded in 1909, Mayoly is an independent French and international pharmaceutical company specialised in Gastroenterology and Dermo-cosmetics.

Following the integration of Ipsen Consumer Healthcare completed in 2022, the combined Company employs over 2,200 people worldwide and generates proforma net sales of €500m, 65% of which generated internationally in more than 100 countries.

Mayoly Group aims to become a global reference in Consumer Healthcare.

Mayoly is a French industrial player committed to supporting patients, every day, in their well-being and health.

For more information, visit www.mayoly-spindler.en or follow us on [LinkedIn](#).